Shares of Yarrow Bioscience (NASDAQ:YARW – Get Free Report) have been given a consensus recommendation of “Moderate Buy” by the five brokerages that are presently covering the company, Marketbeat.com reports. One investment analyst has rated the stock with a sell rating and four have given a buy rating to the company. The average 1-year target price among brokerages that have issued ratings on the stock in the last year is $52.67.
A number of brokerages have recently issued reports on YARW. Jefferies Financial Group set a $40.00 target price on Yarrow Bioscience and gave the stock a “buy” rating in a research report on Monday. TD Cowen assumed coverage on Yarrow Bioscience in a report on Tuesday, July 28th. They set a “buy” rating for the company. Guggenheim began coverage on Yarrow Bioscience in a research report on Friday, November 6th. They issued a “buy” rating and a $60.00 price target for the company. Wall Street Zen upgraded Yarrow Bioscience to a “hold” rating in a research report on Saturday, August 22nd. Finally, BTIG Research began coverage on Yarrow Bioscience in a research note on Monday, August 3rd. They issued a “buy” rating and a $58.00 price target on the stock.
Read Our Latest Report on Yarrow Bioscience
Institutional Inflows and Outflows
Several hedge funds and other institutional investors have recently made changes to their positions in YARW. Braidwell LP purchased a new position in shares of Yarrow Bioscience in the second quarter worth approximately $596,000. Susquehanna International Group LLP purchased a new stake in shares of Yarrow Bioscience in the 2nd quarter valued at approximately $77,000. Two Sigma Securities LLC purchased a new stake in shares of Yarrow Bioscience in the 2nd quarter valued at approximately $26,000. Nantahala Capital Management LLC purchased a new stake in shares of Yarrow Bioscience in the 2nd quarter valued at approximately $1,301,400,000. Finally, ADAR1 Capital Management LLC acquired a new position in Yarrow Bioscience in the 2nd quarter worth approximately $1,920,000. 83.78% of the stock is currently owned by institutional investors and hedge funds.
Yarrow Bioscience Price Performance
Shares of NASDAQ:YARW opened at $18.03 on Monday. Yarrow Bioscience has a one year low of $12.39 and a one year high of $46.95. The firm’s fifty day moving average is $21.88. The firm has a market cap of $48.14 million, a P/E ratio of -1.23 and a beta of 2.10.
Yarrow Bioscience (NASDAQ:YARW – Get Free Report) last released its quarterly earnings data on Thursday, November 12th. The company reported ($0.43) earnings per share for the quarter. Yarrow Bioscience had a negative return on equity of 99.84% and a negative net margin of 4,726.21%.
Yarrow Bioscience Company Profile
VYNE Therapeutics Inc., a pharmaceutical company, focuses on developing various therapeutics for the treatment of immuno-inflammatory conditions. The company develops FCD105, a topical combination foam that has completed Phase III clinical trials for the treatment of moderate-to-severe acne vulgaris; and FMX114, a combination of tofacitinib, which is in Phase IIa preclinical trial for the treatment of mild-to-moderate atopic dermatitis. It is also developing VYN201, a bromodomain and extra-terminal (BET) inhibitor for various immuno-inflammatory diseases, including skin diseases; and VYN202, BET inhibitor compounds that are selective for bromodomain 2.
Featured Stories
- Five stocks we like better than Yarrow Bioscience
- Intuitive Machines’ Business Is Taking Off—Will Its Stock Follow?
- The Next Big Thing May Not Be One Thing: Inside Lazard’s Megatrends ETF
- 3 Power and Grid Stocks That Could Keep Growing Even if AI Spending Slows
- Applied Materials Beats and Raises, But Investors Stay Unconvinced
Receive News & Ratings for Yarrow Bioscience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Yarrow Bioscience and related companies with MarketBeat.com's FREE daily email newsletter.
